Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Tissue ... the regenerative medical devices company, announces that it ... wound care market as Tissue Regenix Wound Care ... Medicare administrator, First Coast Service Options Inc. ("First ... , Puerto Rico and ...
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... -- Insulet Corporation (NASDAQ: PODD ), the leader ... Insulin Management System, today announced preliminary revenue results ... Company also announced that it will postpone the full ... call from Thursday, July 30, as originally scheduled.   ... , Preliminary second quarter revenue results: ...
Breaking Medicine Technology:Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:7/30/2015)... , ... July 30, 2015 , ... Quintessa Medical Spa ... is a nonsurgical treatment designed specifically for the elimination of excess tissue ... the first locations in the state of Wisconsin to offer this innovative treatment. , ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Gummy smile ... lip lowering, gum contouring and surgery, as well as the patented gum depigmentation treatmet. ... has made him popular with many patients from around the world. , “Like treatment ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... entity on behalf of the New Jersey Department of Health, has received a ... Technology, an agency of the U.S. Department of Health and Human Services (HHS). ...
(Date:7/30/2015)... ... ... New research finds some distinct differences in the way mesothelioma behaves in younger ... website. , Researchers with the National Institutes of Health, the FDA, and the ... between 1990 and 2010. Two percent of these cases (207) occurred in people younger ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2
... ... for Healthcare Professionals. , ... Bristol, TN (PRWEB) February 3, 2010 -- King Pharmaceuticals, Inc. ... tools, and essential resources to healthcare professionals and others, helping them provide optimal, ...
... ... American Heart Association’s “Go Red for Women” event in Denver, Colorado. , ... Independence, OH (PRWeb) February 3, ... Red for Women” event in Denver, Colorado. The “Speak Up To Save Lives” ...
... , ... to help healthcare professionals with health literacy solutions for the 90 million literacy challenged ... ... for Healthcare Advancement (IHA), a not-for-profit healthcare organization and a national leader in health ...
... ... In this day and age of specialization and compartmentalization, liberal arts and ... study. For individuals who desire a well-rounded, more classical education, a ... subjects can range from communications and journalism to general arts and the ...
... WASHINGTON , Feb. 2 Sanford Wittels ... announced today that AtriCure, Inc., a medical device company specializing in ... Department of Justice (DOJ) and the Office of the Inspector General ... million plus interest over a five-year period. Sanford Wittels ...
... better, study found , TUESDAY, Feb. 2 (HealthDay News) -- ... will be able to kick the habit and reduces the ... found. , The study included 568 adults who smoked 10 ... year. The smokers who used nicotine patches for the entire ...
Cached Medicine News:Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 2Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 3Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 4Health News:Life Line Screening Supports the American Heart Association's 'Go Red for Women' Event in Denver, Colorado 2Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 2Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 3Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 2Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 3Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 4Health News:Relator's Attorneys Comment on AtriCure/DOJ Settlement 2Health News:Relator's Attorneys Comment on AtriCure/DOJ Settlement 3Health News:Using Nicotine Patch Longer Boosts Efforts to Quit 2
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: